Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes

The percentage manifesting dysplasia in bone marrow needed to qualify as significant is ≥10 % in each lineage. However, detailed analyses of this threshold have not been reported. Here, we analyzed dyserythropoiesis (dysE) in 109 myelodysplastic syndromes (MDS) patients with 21 immune thrombocytopen...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2016-02, Vol.103 (2), p.227-233
Main Authors: Kawai, Nobutaka, Matsuda, Akira, Jinnai, Itsuro, Ichimura, Takaya, Kayano, Hidekazu, Okamura, Daisuke, Ishikawa, Maho, Maeda, Tomoya, Hata, Tomoko, Miyazaki, Yasushi, Asou, Norio, Bessho, Masami, Tomonaga, Masao
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Bone Marrow - pathology
Datasets as Topic
Erythroblasts - pathology
Erythropoiesis
Female
Hematology
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Myelodysplastic syndromes
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - pathology
Oncology
Original Article
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The percentage manifesting dysplasia in bone marrow needed to qualify as significant is ≥10 % in each lineage. However, detailed analyses of this threshold have not been reported. Here, we analyzed dyserythropoiesis (dysE) in 109 myelodysplastic syndromes (MDS) patients with 21 immune thrombocytopenia (ITP)/12 hemolytic anemia (HA) patients as a control. In present study, mild megaloblastic erythroblasts were specifically named ‘red cell with abnormal chromatin clumping (RCACC)’. RCACC ≥10 % in erythroblasts was observed in 29 % of ITP patients and 58 % of HA patients. The numbers of MDS patients with RCACC in erythroblasts
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-015-1916-8